X
Translate:
Media Inquiries?
Please call

08/27/20

RUTGERS NEW JERSEY MEDICAL SCHOOL AND UNIVERSITY HOSPITAL BEGIN RECRUITING HEALTHY ADULTS FOR COVID-19 VACCINE CLINICAL TRIAL

Rutgers New Jersey Medical School (NJMS) and University Hospital (UH) announced today that they are recruiting healthy adults for a Phase 3 clinical research study to evaluate the safety and effectiveness of mRNA-1273, a vaccine candidate against COVID-19. Sponsored by Moderna, the COVE Study is recruiting healthy volunteers ages 18 or older in high-risk populations, including the elderly, racial and ethnic minorities at higher risk for COVID-19, and essential workers in close contact with potentially infected persons.

The Phase 3 study will evaluate if mRNA-1273 boosts the immune system to produce enough antibodies against SARS-CoV-2, the virus that causes COVID-19, so it does not cause illness in case of infection.

“We are excited and hopeful as we begin participating in the COVE Study, understanding this is one of the most important and impactful clinical research studies in our lifetime,” said Shobha Swaminathan, Principal Investigator, Rutgers NJMS and Medical Director, Infectious Diseases Practice, UH. “We encourage individuals across the state to consider participating in this trial, which could bring the world one step closer to ending this global health crisis.”

To be eligible for the study, healthy volunteers must be 18 years of age and older with no known history of SARS-CoV-2 infection or previous participation in an investigational coronavirus vaccine. Within this population, Rutgers NJMS and UH, Newark, NJ are prioritizing candidates whose locations or circumstances put them at higher risk of exposure to the virus, including:

  • Elderly, ages 65 and older
  • Essential workers in close contact with potentially infected persons, including, but not limited to, healthcare and hospital workers, first responders, transit employees, institutional residents or workers, factory employees, and teachers and students
  • Racial and ethnic minorities at high risk for COVID-19

If a person is eligible and decides to participate, the research staff at Rutgers NJMS will randomize patients to receive either the mRNA-1273 vaccine or a matching placebo. The total length of participation is 25 months and includes approximately six visits to the clinic and 25 phone calls.

Rutgers NJMS is one of 89 research sites across the country participating in the COVE Study. If someone is interested in participating in clinical research in their area, call 1 844-782-6765 or email thecovestudy@njms.rutgers.edu to learn more.

Other Recent News Stories
06/04/24

University Hospital Welcomes Dr. Paul J. Gaglio as Director of Liver Disease and Transplant Hepatology

UNIVERSITY HOSPITAL WELCOMES DR. PAUL J. GAGLIO AS DIRECTOR OF LIVER DISEASE AND TRANSPLANT HEPATOLOGY University Hospital is pleased to announce that Paul J. Gaglio, MD FACP, AGAF, FAASLD, has been named the Director of the Division of Liver Disease and Transplant Hepatology as well as the Medical Director of Liver Transplantation at University Hospital …

University Hospital Welcomes Dr. Paul J. Gaglio as Director of Liver Disease and Transplant Hepatology Read More »

More
01/17/24

FOR IMMEDIATE RELEASE       MEDIA CONTACT   January 17, 2024 media@uhnj.org, (973) 634-8298    UNIVERSITY HOSPITAL AND RUTGERS NEW JERSEY MEDICAL SCHOOL LAUNCH COMPREHENSIVE WEIGHT MANAGEMENT CENTER    Ribbon Cutting Unveils New Rutgers Weight Management Center at University Hospital      Newark, NJ— Today, University Hospital proudly launched a new multidisciplinary Weight Management Center in partnership …

Read More »

More
01/10/24

UNIVERSITY HOSPITAL WELCOMES NEW CHIEF COMPLIANCE AND PRIVACY OFFICER

UNIVERSITY HOSPITAL WELCOMES NEW CHIEF COMPLIANCE AND PRIVACY OFFICER NEWARK, NJ — University Hospital today announced the appointment of Astara Crews as its new Chief Compliance Officer. Astara will assume a crucial role in the hospital’s executive leadership team, overseeing compliance initiatives and contributing to the institution’s commitment to providing high-quality healthcare to the Newark …

UNIVERSITY HOSPITAL WELCOMES NEW CHIEF COMPLIANCE AND PRIVACY OFFICER Read More »

More
Scroll to Top